Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,
The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond analysts' top-and-bottom-line estimates for Regeneron (REGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte
Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on wh
Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.
Regeneron (REGN) is a Buy ahead of Q2 2026 earnings: Dupixent, Eylea HD, and Libtayo growth plus pipeline catalysts and $3B buyback. Read the latest analysis on the stock here.
View interactive chart, options flow, and AI analysis for REGN on Zorveq Finance.
Open REGN Chart & Analysis →